AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Achilles Therapeutics PLC ADR (NASDAQ:ACHL)
-- USD
0.000 0.000%Sponsored Reports
Loading...
| Previous Close (in USD) | -- |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 1.760/0.630 |
| EBITDA (in USD) | -65.899M |
| PE Ratio | -- |
| Volume | -- |
| Diluted Eps TTM | -1.66 |
| Total Assets (in USD) | 161.456M |
|---|---|
| Total Liabilities (in USD) | 19.087M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 131.539M |
| Market Cap (in USD) | 44.852 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Achilles Therapeutics PLC ADR
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Employees: 204
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Iraj Ali | CEO & Director | 1976 |
| 2. | Dr. Karl Peggs M.D. | Founder & Chief Medical Officer | 1967 |
| 3. | Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D. | Founder | 1963 |
| 4. | Dr. Charles Swanton FMEDSCI, M.D., Ph.D. | Founder | 1973 |
| 5. | Dr. Sergio A. Quezada Ph.D. | Founder & Chief Scientific Officer | 1976 |
| 6. | Mr. Robert Coutts | Chief Financial Officer | 1984 |
| 7. | Mr. Lee M. Stern | VP of Investor Relations & External Communications | NA |
| 8. | Mr. Daniel Hood | Gen. Counsel & Company Sec. | NA |
| 9. | Julia Wilson | Head of Communications | NA |
| 10. | Mr. Tariq Ahmed | VP of People | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.850 1.219% | 70.245 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.320 1.881% | 71.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+5.035 1.135% | 445 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+13.950 2.725% | 515.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -71.065M | -61.062M | -33.196M | -13.99M | - |
| Minority Interest | - | - | - | - | - |
| Net Income | -71.176M | -61.099M | -33.199M | -13.99M | - |
| Selling General Administrative | 21.12M | 21.971M | 11.098M | 4.703M | - |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 3.69M | 3.288M | 0.772M | 0.302M | - |
| Ebit | -78.383M | -64.195M | -33.727M | -13.775M | -6.901M |
| Ebitda | -74.693M | -60.907M | -32.955M | -13.473M | - |
| Depreciation And Amortization | 3.69M | 3.288M | 0.772M | 0.302M | - |
| Operating Income | -78.383M | -64.195M | -33.727M | -13.775M | - |
| Other Operating Expenses | 78.383M | 64.195M | 33.727M | 13.775M | - |
| Interest Expense | 7.318M | 3.133M | 0.531M | 0.215M | 0M |
| Tax Provision | 0.111M | 0.037M | 0.003M | 0M | - |
| Interest Income | - | - | - | - | - |
| Net Interest Income | - | - | - | - | - |
| Income Tax Expense | 0.111M | 0.037M | 0.003M | 0.215M | - |
| Total Revenue | 0M | 0M | 0M | 0M | - |
| Total Operating Expenses | 78.383M | 64.195M | 33.727M | 13.775M | - |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 7.318M | 3.133M | 0.531M | -0.215M | - |
| Net Income From Continuing Ops | -71.176M | -61.099M | -33.199M | -13.99M | - |
| Net Income Applicable To Common Shares | -71.176M | -61.099M | -33.199M | -13.99M | -6.887M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 161.456M | 220.358M | 317.106M | 218.918M | 105.205M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 3.743M | 2.615M | 2.124M | 0.851M | 0.477M |
| Total Liab | 19.087M | 23.314M | 27.578M | 29.546M | 3.857M |
| Total Stockholder Equity | 142.369M | 197.044M | 289.528M | 189.372M | 101.348M |
| Other Current Liab | 13.457M | 8.618M | 1.268M | 1.37M | 0.681M |
| Common Stock | 0.182M | 0.054M | 0.054M | 0.025M | 0.014M |
| Capital Stock | 0.054M | 0.054M | 0.182M | 0.159M | 0.093M |
| Retained Earnings | -259.952M | -190.287M | -119.111M | -58.012M | -24.813M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 3.298M | 3.566M | 3.012M | 0.034M |
| Cash | 131.539M | 173.338M | 266.319M | 177.849M | 97.594M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 16.996M | 17.993M | 19.11M | 16.623M | 3.857M |
| Current Deferred Revenue | -5.629M | - | 9.638M | 5.227M | 1.787M |
| Net Debt | -126.924M | -164.762M | -254.06M | -161.866M | -97.107M |
| Short Term Debt | 3.539M | 4.188M | 4.482M | 3.712M | 0.487M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 4.615M | 8.576M | 12.259M | 15.983M | 0.487M |
| Other Stockholder Equity | 415.21M | 408.972M | 401.949M | 234.903M | 117.959M |
| Property Plant Equipment | - | 20.48M | 28.791M | 28.109M | 2.11M |
| Total Current Assets | 145.633M | 196.58M | 284.749M | 187.797M | 103.061M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 10.351M | 16.003M | 11.173M | 7.339M | 4.486M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 0M | 4.624M | 5.133M | 1.758M | 0.504M |
| Accounts Payable | 5.629M | 5.187M | 3.722M | 6.314M | 0.902M |
| Accumulated Other Comprehensive Income | -13.071M | -21.695M | 6.636M | 12.322M | 8.109M |
| Non Currrent Assets Other | 2.206M | 3.047M | 3.54M | 3.008M | 0.034M |
| Non Current Assets Total | 15.823M | 23.778M | 32.357M | 31.121M | 2.144M |
| Capital Lease Obligations | 4.615M | 8.576M | 12.259M | 15.983M | 0.487M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -7.512M | -7.634M | -11.847M | -0.942M | - |
| Total Cashflows From Investing Activities | -7.512M | -7.634M | -11.847M | -0.942M | -0.258M |
| Total Cash From Financing Activities | 0.001M | 160.755M | 113.704M | 93.622M | 13.511M |
| Net Income | -71.176M | -61.099M | -33.199M | -13.99M | -6.887M |
| Change In Cash | -92.981M | 88.503M | 80.255M | 86.911M | 5.702M |
| Begin Period Cash Flow | 266.352M | 177.849M | 97.594M | 10.683M | - |
| End Period Cash Flow | 173.371M | 266.352M | 177.849M | 97.594M | 10.683M |
| Total Cash From Operating Activities | -59.535M | -59.284M | -25.252M | -14.142M | -7.598M |
| Depreciation | 3.69M | 3.288M | 0.772M | 0.302M | 0.173M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | - | - |
| Other Cashflows From Financing Activities | -7.512M | -7.634M | 113.704M | -0.942M | -0.121M |
| Capital Expenditures | 7.512M | 7.634M | 11.847M | 0.942M | 0.258M |
| Change In Working Capital | -5.956M | -7.931M | 3.004M | -1.178M | - |
| Other Non Cash Items | 6.885M | -0.018M | 1.179M | -0.009M | - |
| Free Cash Flow | -67.047M | -66.918M | -37.099M | -15.084M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Nasdaq Composite Index | 7 months ago | 21590 |
| 2. | Blackstone Alternative Multi-Strategy I | 11 months ago | 100 |
| 3. | LUX IM Global Medtech HX | 1 year ago | 17900 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Syncona Portfolio Ltd. | 8 months ago | 11086909 |
| 2. | BML Capital Management LLC | 8 months ago | 4100002 |
| 3. | FCPM III SERVICES BV | 8 months ago | 2390050 |
| 4. | Redmile Group, LLC | 8 months ago | 1608089 |
| 5. | Vestal Point Capital LP | 8 months ago | 1500000 |
| 6. | Ikarian Capital, LLC | 8 months ago | 1443181 |
| 7. | Renaissance Technologies Corp | 8 months ago | 638133 |
| 8. | BOOTHBAY FUND MANAGEMENT, LLC | 8 months ago | 420481 |
| 9. | Virtu Financial LLC | 11 months ago | 22813 |
| 10. | Two Sigma Advisers, LLC | 8 months ago | 22400 |
| 11. | Geode Capital Management, LLC | 8 months ago | 21590 |
| 12. | Two Sigma Investments LLC | 8 months ago | 21249 |
| 13. | Corsair Capital Management LLC | 8 months ago | 20000 |
| 14. | Morgan Stanley - Brokerage Accounts | 8 months ago | 16431 |
| 15. | Baader Bank INC | 8 months ago | 14184 |
| 16. | Susquehanna International Group, LLP | 8 months ago | 12434 |
| 17. | Brave Asset Management Inc | 8 months ago | 10000 |
| 18. | Rhumbline Advisers | 8 months ago | 4480 |
| 19. | Arcadia Investment Management Corp | 8 months ago | 3000 |
| 20. | JPMorgan Chase & Co | 8 months ago | 137 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...